Sun Pharmaceutical had sought grant of 'emergency authorisation status' to its plant-based drug, ACQH, which is being developed as a potential treatment for dengue.
Sun Pharma said human safety study of AQCH already completed, clinical trials will be conducted across 12 centres on 210 patients. The treatment duration will be 10 days.
The Mumbai-based drug-maker has submitted a proposal to the govt to conduct Phase II clinical trials of the drug to see if it can treat patients suffering from Covid-19.
The latest probe points to challenges for India’s biggest drugmaker after whistle-blower complaints on corporate governance lapses triggered a stock slide last year.
In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.
Discriminatory laws limit firms from hiring willing women, and removing such barriers can help narrow the economic gap between developing and developed countries.
While bond yields tend to fall amid low inflation & interest rate cuts, market experts say they’ve been rising due to concerns over tax collections, fiscal deficit & potential impact of US tariffs.
A panel of experts moderated by ThePrint’s Editor-in-Chief Shekhar Gupta drew connections between insights of 1965 Indo-Pak War and strategic takeaways highlighted by Op Sindoor.
In its toughest time in decades because of floods, Punjab would’ve expected PM Modi to visit. If he has the time for a Bihar tour, why not a short visit to next-door Punjab?
COMMENTS